THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance the development of two drug ...
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and ...
The U.S. Food and Drug Administration has approved Brineura (cerliponase alfa) to treat a specific form of Batten Disease, a condition that typically starts between 2 and 4 years of age. The newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results